DMC recommends Celgene to discontinue Phase III Mainsail trial
The pivotal double-blinded trial was designed to assess the safety and efficacy of docetaxel and prednisone with or without lenalidomide in patients with castrate-resistant prosta te cancer (CRPC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.